Skip to main content
. 2022 Jul 16;127(7):1304–1311. doi: 10.1038/s41416-022-01913-4

Fig. 3. Landscape of actionable oncogenic alterations in MSI-H and MSS CRCs.

Fig. 3

a Actionable mutations grouped by RAS/RAF/MEK, PI3K/mTOR, HRR and RTK pathways. Percentage of patients with wild-type RAS/RAF plus at least one off-label indication was framed with dash line. b Comparison of percent pathway altered between the early-stage and the late-stage CRCs in MSI-H and MSS subtypes.